Orexo strives to ensure that analysts, investors and financial media are provided with correct and timely information. We will also build and maintain relationships based on credibility. In this way we contribute to an accurate valuation of the Company. Orexo’s share is listed on Nasdaq Stockholm and available as American Depository Receipts (ADRs) on OTCQX in the US.
MAY 11, 2020 – Today Orexo announces it has acquired the US rights to commercialize deprexis®, a world-leading digital therapy to manage depression. In the wake of the COVID-19 pandemic the need for digital therapies is unprecedented and the company will accelerate the US launch of its three therapies, also including vorvida® and OXD01, in 2020.
APRIL 28, 2020 – In Q1 a solid financial performance was reported, with both profitability and cash improving. The main driver was Zubsolv US with an EBIT margin of 46 percent. The impact of COVID-19 has been limited and the timelines for OX125 and OX124 is unchanged at this stage. In parallel the company is assessing to accelerate the launch of vorvida® and OXD01 in the US.
APRIL 16, 2020 – On May 19 Orexo will held an extraordinary general meeting at it´s headquarter in Uppsala, Sweden. Latest day for registration is May 13 and before attending in person please read our COVID-19 visitation policy. For access to all documents related to our EGM go to About US/Corporate Governance on our website and scroll down to the EGM section or press the link below.
MARCH 17, 2020 – On the Capital Markets Day today the company will present the sales potential for both the pharma projects and the digital therapies. Among others OX124 is expected to reach a sales potential of USD 70 m – USD 110 m in the US.
